Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major
depressive disorder (depression) who have responded inadequately to another antidepressant
drug during the current episode. This trial will assess the effects of GLYX-13 on depression
when added to another antidepressant drug that the patient is already taking.
Phase:
Phase 2
Details
Lead Sponsor:
Naurex, Inc Naurex, Inc, an affiliate of Allergan plc